Data completeness
2/8 — Basic
SOMOPHYLLIN (aminophylline) by Pfizer is mechanism of action: theophylline has two distinct actions in the airways of patients with reversible obstruction; smooth muscle relaxation (i.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SOMOPHYLLIN is an aminophylline rectal enema formulation that acts as a bronchodilator and airway prophylactic agent for patients with reversible airway obstruction. It works through inhibition of phosphodiesterase isozymes (PDE III and PDE IV) to relax smooth muscle and suppress airway hyperresponsiveness, with therapeutic benefit occurring at serum theophylline concentrations of 10–15 mcg/mL.
Pre-Launch
Pre-launch stage indicates early-phase commercial buildout; teams are focused on regulatory completion, manufacturing scale-up, and launch readiness rather than peak revenue generation.
Mechanism of Action
Mechanism of Action: Theophylline has two distinct actions in the airways of patients with reversible obstruction; smooth muscle relaxation (i.e., bronchodilation) and suppression of the response of the airways to stimuli (i.e., nonbronchodilator prophylactic effects). While the mechanisms of…
Indications
Worked on SOMOPHYLLIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.